2004
DOI: 10.1097/01.coc.0000128861.46357.ee
|Get access via publisher |Summarize |Cite
|
Sign up to set email alerts

Nonocular Second Primary Tumors After Retinoblastoma

Abstract: The objective of this study was to assess the role of various clinical and treatment factors involved in the long-term incidence of nonocular second primary tumors following retinoblastoma. The study was based on 111 patients treated between 1963 and 1977 according to the same radiotherapy protocol (electron beam radiotherapy) alone or in combination with triethylene melamine (TEM). Various statistical methods were used to obtain the actuarial survival curve, the cumulative incidence of second primary tumors, … Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
26
1
0
0

Citation Types

0
2
0
0

Year Published

Range
2000
2000
2021
2021

Publication Types

Select...
21
6

Relationship

2
25

Authors

Journals

citations

Cited by 27 publications

(2 citation statements)
references

References 50 publications

0
2
0
0
Order By: Relevance
How this paper cites the one you are viewing
“…Histologically, the most commonly reported SPTs are bone osteogenic sarcomas, soft‐tissue sarcomas, melanomas, epithelial tumors, intracranial meningeal, or brain tumors and, more rarely, leukemias and lymphomas . The risk factors for the occurrence of SPTs in the survivors of germline retinoblastoma are not only related to the genetic predisposition.…”
Section: Introduction
mentioning
confidence: 99%
“…5 Histologically, the most commonly reported SPTs are bone osteogenic sarcomas, soft-tissue sarcomas, melanomas, epithelial tumors, intracranial meningeal, or brain tumors and, more rarely, leukemias and lymphomas. [5][6][7][8][9][10][11] The risk factors for the occurrence of SPTs in the survivors of germline retinoblastoma are not only related to the genetic predisposition. A well-established risk factor is previous treatment by external beam radiotherapy (EBRT), 12 which was commonly used few decades ago for the conservative treatment of retinoblastoma.…”
Section: Introduction
mentioning
confidence: 99%
See 1 more Smart Citation